(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.

The three biggest winners today are Yunji, NASDAQ TEST STOCK, and Wave Life Sciences Ltd..

The three biggest losers today are Youngevity International, Castle Biosciences, and EPAM Systems.

Winners today

1. Yunji (YJ) – 50.87%

Yunji Inc. operates a social e-commerce platform in the People's Republic of China. It offers a range of product categories that cater various daily needs of users and their households, including beauty and personal care, household goods, cloths, food and fresh produce, computer and electronics, apparel, bags and cases, baby and maternity products, and home appliances. The company was founded in 2015 and is headquartered in Hangzhou, the People's Republic of China.

NASDAQ ended the session with Yunji rising 50.87% to $0.32 on Monday while NASDAQ fell 0.09% to $13,229.43.

Earnings Per Share

As for profitability, Yunji has a trailing twelve months EPS of $-0.16.

Moving Average

Yunji’s value is above its 50-day moving average of $0.32 and way below its 200-day moving average of $0.61.

Yearly Top and Bottom Value

Yunji’s stock is valued at $0.32 at 17:32 EST, way below its 52-week high of $1.19 and way higher than its 52-week low of $0.18.

More news about Yunji.

2. NASDAQ TEST STOCK (ZVZZT) – 17.98%

NASDAQ ended the session with NASDAQ TEST STOCK jumping 17.98% to $14.37 on Monday, after five sequential sessions in a row of losses. NASDAQ slid 0.09% to $13,229.43, after two sequential sessions in a row of gains, on what was a somewhat negative trend exchanging session today.

Yearly Top and Bottom Value

NASDAQ TEST STOCK’s stock is valued at $14.37 at 17:32 EST, way below its 52-week low of $11.00.

More news about NASDAQ TEST STOCK.

3. Wave Life Sciences Ltd. (WVE) – 9.38%

Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces of novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. The company is primarily developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. It focuses on programs in neurology in the central nervous system and neuromuscular system. The company has a research, license, and option agreement with Pfizer Inc. and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of stereopure oligonucleotide therapeutics and oligonucleotide therapeutics; and research, development, and develop antisense oligonucleotides. Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore.

NASDAQ ended the session with Wave Life Sciences Ltd. jumping 9.38% to $4.55 on Monday while NASDAQ dropped 0.09% to $13,229.43.

Earnings Per Share

As for profitability, Wave Life Sciences Ltd. has a trailing twelve months EPS of $-1.95.

Volume

Today’s last reported volume for Wave Life Sciences Ltd. is 422765 which is 17.99% above its average volume of 358303.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Wave Life Sciences Ltd.’s EBITDA is 16.07.

More news about Wave Life Sciences Ltd..

4. WW International (WW) – 9.1%

WW International, Inc. provides weight management products and services worldwide. The company operates in four segments: North America, Continental Europe, United Kingdom, and Other. It offers a range of nutritional, activity, behavioral, and lifestyle tools and approaches products and services. The company also provides various digital subscription products to wellness and weight management business, which provide interactive and personalized resources that allow users to follow its weight management program via its Web-based and mobile app products, including personal coaching and digital products; and allows members to inspire and support each other by sharing their experiences with other people on weight management and wellness journeys. In addition, it offers various consumer products, including bars, snacks, cookbooks, kitchen tools, and other products. Further, the company licenses its trademarks and other intellectual property in food, beverages, and other consumer products and services. It offers products through its e-commerce platform, workshops, magazine subscriptions, retail partners, publishing, and third-party advertising in publications; and through Websites and sales from the By Mail product. The company was formerly known as Weight Watchers International, Inc. and changed its name to WW International, Inc. in September 2019. WW International, Inc. was founded in 1961 and is headquartered in New York, New York.

NASDAQ ended the session with WW International jumping 9.1% to $7.19 on Monday, after two consecutive sessions in a row of gains. NASDAQ dropped 0.09% to $13,229.43, after two consecutive sessions in a row of gains, on what was a somewhat negative trend exchanging session today.

Earnings Per Share

As for profitability, WW International has a trailing twelve months EPS of $-5.63.

Growth Estimates Quarters

The company’s growth estimates for the current quarter and the next is 214.3% and 104.1%, respectively.

Volume

Today’s last reported volume for WW International is 3200680 which is 63.63% below its average volume of 8801880.

Revenue Growth

Year-on-year quarterly revenue growth declined by 18.8%, now sitting on 984.99M for the twelve trailing months.

More news about WW International .

5. MicroVision (MVIS) – 8.71%

MicroVision, Inc. develops and sells lidar sensors used in automotive safety and autonomous driving applications. Its laser beam scanning technology is based on micro-electrical mechanical systems (MEMS), laser diodes, opto-mechanics, electronics, algorithms, and software. The company also develops micro-display concepts and designs for head-mounted augmented reality (AR) headsets, as well as 1440i MEMS module supporting AR headsets; interactive display solutions for the smart speakers market; and Consumer Lidar used in smart home systems. In addition, it develops 1st Generation LRL module. The company sells its products primarily to original equipment manufacturers and original design manufacturers. MicroVision, Inc. was founded in 1993 and is headquartered in Redmond, Washington.

NASDAQ ended the session with MicroVision jumping 8.71% to $5.34 on Monday while NASDAQ fell 0.09% to $13,229.43.

Earnings Per Share

As for profitability, MicroVision has a trailing twelve months EPS of $-0.37.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -62.05%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 123.4%, now sitting on 1.1M for the twelve trailing months.

More news about MicroVision.

6. Matterport
(MTTR) – 7.85%

Matterport, Inc., a spatial data company, focuses on digitization and datafication of the built world. The company offers Matterport Capture Services, a fully managed solution for enterprise subscribers; Smartphone Capture, a smartphone capture solution for both iOS and Android; Matterport Pro3, a 3D camera that scans properties; Matterport Pro2, a 3D camera that captures spaces; and 360 Cameras. It also provides Matterport Axis, a motorized mount that can be used with the Matterport Capture app to capture 3D digital twins of any physical space with increased speed, precision, and consistency. It offers solutions for residential and commercial real estate, facilities management and retail, AEC, insurance and repair, and travel and hospitality. Matterport, Inc. is headquartered in Sunnyvale, California.

NASDAQ ended the session with Matterport
jumping 7.85% to $2.82 on Monday, after four consecutive sessions in a row of losses. NASDAQ dropped 0.09% to $13,229.43, after two sequential sessions in a row of gains, on what was a somewhat bearish trend exchanging session today.

Earnings Per Share

As for profitability, Matterport
has a trailing twelve months EPS of $-0.75.

Volatility

Matterport
‘s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.53%, a positive 0.02%, and a positive 3.16%.

Matterport
‘s highest amplitude of average volatility was 5.27% (last week), 2.86% (last month), and 3.16% (last quarter).

More news about Matterport
.

7. Matterport
(MTTR) – 7.85%

Matterport, Inc., a spatial data company, focuses on digitization and datafication of the built world. The company offers Matterport Capture Services, a fully managed solution for enterprise subscribers; Smartphone Capture, a smartphone capture solution for both iOS and Android; Matterport Pro3, a 3D camera that scans properties; Matterport Pro2, a 3D camera that captures spaces; and 360 Cameras. It also provides Matterport Axis, a motorized mount that can be used with the Matterport Capture app to capture 3D digital twins of any physical space with increased speed, precision, and consistency. It offers solutions for residential and commercial real estate, facilities management and retail, AEC, insurance and repair, and travel and hospitality. Matterport, Inc. is headquartered in Sunnyvale, California.

NASDAQ ended the session with Matterport
jumping 7.85% to $2.82 on Monday while NASDAQ fell 0.09% to $13,229.43.

Earnings Per Share

As for profitability, Matterport
has a trailing twelve months EPS of $-0.75.

Yearly Top and Bottom Value

Matterport
‘s stock is valued at $2.82 at 17:32 EST, way below its 52-week high of $7.45 and way above its 52-week low of $2.20.

Sales Growth

Matterport
‘s sales growth is 37.8% for the present quarter and 16.2% for the next.

Volatility

Matterport
‘s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.53%, a positive 0.02%, and a positive 3.16%.

Matterport
‘s highest amplitude of average volatility was 5.27% (last week), 2.86% (last month), and 3.16% (last quarter).

More news about Matterport
.

8. FibroGen (FGEN) – 7.77%

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and Duchenne muscular dystrophy; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

NASDAQ ended the session with FibroGen jumping 7.77% to $19.27 on Monday, after four consecutive sessions in a row of gains. NASDAQ slid 0.09% to $13,229.43, after two consecutive sessions in a row of gains, on what was a somewhat bearish trend exchanging session today.

Earnings Per Share

As for profitability, FibroGen has a trailing twelve months EPS of $-3.39.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -411.93%.

Moving Average

FibroGen’s worth is higher than its 50-day moving average of $18.06 and way above its 200-day moving average of $17.30.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, FibroGen’s stock is considered to be oversold (<=20).

More news about FibroGen.

9. Xeris Pharmaceuticals (XERS) – 7.63%

Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technology platforms allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, small molecules, and proteins using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps. The company's lead product candidate is Gvoke HypoPen for the treatment of severe hypoglycemia, a potentially life-threatening condition in people with diabetes. Its product candidates also comprise ready-to-use glucagon that has completed Phase II clinical trials for the treatment of post-bariatric hypoglycemia, exercise-induced hypoglycemia in diabetes, bi-hormonal artificial pancreas closed-loop systems, congenital hyperinsulinism, and hypoglycemia-associated autonomic failure; and hypoglycemia associated with intermittent and chronic conditions. In addition, it develops ready-to-use diazepam formulation, which is in Phase Ib clinical trial for the treatment of Dravet syndrome and acute repetitive seizures in patients with epilepsy; and Pramlintide-Insulin co-formulation that is Phase II clinical trials for treating type 1 and 2 diabetes. Xeris Pharmaceuticals, Inc. serves patients, caregivers, and health practitioners. The company was founded in 2005 and is headquartered in Chicago, Illinois.

NASDAQ ended the session with Xeris Pharmaceuticals rising 7.63% to $2.82 on Monday while NASDAQ slid 0.09% to $13,229.43.

Earnings Per Share

As for profitability, Xeris Pharmaceuticals has a trailing twelve months EPS of $-0.63.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -122.97%.

More news about Xeris Pharmaceuticals.

10. Valley National Bancorp (VLY) – 7.53%

Valley National Bancorp operates as the holding company for the Valley National Bank that provides commercial, retail, insurance, and wealth management financial services. The company operates through Commercial Lending, Consumer Lending, and Investment Management segments. Its deposit products include non-interest bearing, savings, NOW, and money market accounts, as well as certificates of deposit. The company offers various loan products comprising residential mortgage loans, automobile loans, secured personal lines of credit, and home equity loans; and floating rate and adjustable rate commercial and industrial loans, as well as fixed rate owner occupied and commercial real estate loans. It also invests in securities and interest-bearing deposits with other banks; and offers international banking services, such as standby letters of credit, documentary letters of credit and related products, and other ancillary services, such as foreign exchange transactions, documentary collections, foreign wire transfers, and transaction accounts for non-resident aliens. In addition, the company provides asset management advisory, trust, and asset-based lending support services; property and casualty, life, health, and title insurance agency services; and health care equipment lending and other commercial equipment leasing services, as well as real estate related investments. Further, it offers other banking services comprising automated teller machine, telephone and Internet banking, remote deposit capturing, overdraft, drive-in and night deposit, and safe deposit services. The company operates 238 branches in New Jersey, New York, Florida, and Alabama. Valley National Bancorp was founded in 1927 and is based in New York, New York.

NASDAQ ended the session with Valley National Bancorp rising 7.53% to $8.00 on Monday, after two consecutive sessions in a row of gains. NASDAQ slid 0.09% to $13,229.43, after two successive sessions in a row of gains, on what was a somewhat down trend trading session today.

Earnings Per Share

As for profitability, Valley National Bancorp has a trailing twelve months EPS of $1.24.

PE Ratio

Valley National Bancorp has a trailing twelve months price to earnings ratio of 6.45. Meaning, the purchaser of the share is investing $6.45 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.31%.

Yearly Top and Bottom Value

Valley National Bancorp’s stock is valued at $8.00 at 17:32 EST, way below its 52-week high of $13.07 and way higher than its 52-week low of $6.39.

Moving Average

Valley National Bancorp’s value is below its 50-day moving average of $8.10 and way under its 200-day moving average of $10.72.

More news about Valley National Bancorp.

Losers Today

1. Youngevity International (YGYI) – -89%

Youngevity International, Inc. develops and distributes health and nutrition related products and services in the United States and internationally. It operates in three segments: Direct Selling, Commercial Coffee, and Commercial Hemp. The company offers nutritional supplements, gourmet coffee, weight management products, skincare and cosmetics, health and wellness, packaged foods, lifestyle products, pet care, digital products, telecare health services, apparel and fashion accessories, and business lending products. It also produces and sells coffee products under the Café La Rica, Café Alma, Josie's Java House, Javalution Urban Grind, Javalution Daily Grind, and Javalution Royal Roast brands; and produces and markets a line of coffees under the JavaFit brand directly to consumers. In addition, it offers cannabidiol oils from hemp stock. The company sells coffee and equipment to wellness and retirement communities, and various cruise lines and coffee service operators, as well as through distribution network. Youngevity International, Inc. also markets its products through a range of consumer Websites, such as youngevity.com; ygyi.com; heritagemakers.com; hempfx.com; clrroasters.com; cafelarica.com; javalution.com. The company was formerly known as AL International, Inc. and changed its name to Youngevity International, Inc. in July 2013. Youngevity International, Inc. was founded in 1996 and is headquartered in Chula Vista, California.

NASDAQ ended the session with Youngevity International dropping 89% to $0.00 on Monday, after five consecutive sessions in a row of losses. NASDAQ fell 0.09% to $13,229.43, after two sequential sessions in a row of gains, on what was a somewhat negative trend exchanging session today.

Earnings Per Share

As for profitability, Youngevity International has a trailing twelve months EPS of $-0.18.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -126.78%.

Volume

Today’s last reported volume for Youngevity International is 2714970 which is 6098% above its average volume of 43804.

Revenue Growth

Year-on-year quarterly revenue growth grew by 1.9%, now sitting on 137.18M for the twelve trailing months.

More news about Youngevity International.

2. Castle Biosciences (CSTL) – -48.79%

Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary 35-GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.

NASDAQ ended the session with Castle Biosciences falling 48.79% to $11.64 on Monday, following the last session’s upward trend. NASDAQ slid 0.09% to $13,229.43, after two successive sessions in a row of gains, on what was a somewhat down trend exchanging session today.

Earnings Per Share

As for profitability, Castle Biosciences has a trailing twelve months EPS of $-2.5.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -18.33%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Castle Biosciences’s EBITDA is 2.42.

Growth Estimates Quarters

The company’s growth estimates for the present quarter and the next is a negative 1433.3% and a negative 15.6%, respectively.

Sales Growth

Castle Biosciences’s sales growth is 25.6% for the ongoing quarter and 30% for the next.

More news about Castle Biosciences.

3. EPAM Systems (EPAM) – -20.57%

EPAM Systems, Inc. provides digital platform engineering and software development services worldwide. The company offers engineering services, including requirements analysis and platform selection, customization, cross-platform migration, implementation, and integration; infrastructure management services, such as software development, testing, and maintenance with private, public, and infrastructure management for application, database, network, server, storage, and systems operations management, as well as monitoring, incident notification, and resolution services; and maintenance and support services. It also provides operation solutions comprising integrated engineering practices and smart automation; and optimization solutions that include software application testing, test management, automation, and consulting services to enable customers enhance their existing software testing and quality assurance practices, as well as other testing services that identify threats and close loopholes to protect its customers' business systems from information loss. In addition, the company offers business, experience, technology, data, and technical advisory consulting services; and digital and service design solutions, which comprise strategy, design, creative, and program management services, as well as physical product development, such as artificial intelligence, robotics, and virtual reality. The company serves the financial services, travel and consumer, software and hi-tech, business information and media, life sciences and healthcare, and other industries EPAM Systems, Inc. was founded in 1993 and is headquartered in Newtown, Pennsylvania.

NYSE ended the session with EPAM Systems dropping 20.57% to $206.25 on Monday, after two successive sessions in a row of gains. NYSE slid 0.35% to $15,291.17, after two sequential sessions in a row of gains, on what was a somewhat down trend exchanging session today.

Earnings Per Share

As for profitability, EPAM Systems has a trailing twelve months EPS of $7.35.

PE Ratio

EPAM Systems has a trailing twelve months price to earnings ratio of 28.06. Meaning, the purchaser of the share is investing $28.06 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.2%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 3.4%, now sitting on 4.86B for the twelve trailing months.

More news about EPAM Systems.

4. Xenetic Biosciences (XBIOW) – -12.55%

NASDAQ ended the session with Xenetic Biosciences sliding 12.55% to $4.46 on Monday while NASDAQ fell 0.09% to $13,229.43.

Yearly Top and Bottom Value

Xenetic Biosciences’s stock is valued at $4.46 at 17:32 EST, way below its 52-week high of $23.16 and way higher than its 52-week low of $0.00.

Moving Average

Xenetic Biosciences’s value is way higher than its 50-day moving average of $2.78 and way above its 200-day moving average of $1.54.

More news about Xenetic Biosciences.

5. Coinbase (COIN) – -11.53%

Coinbase Global, Inc. provides financial infrastructure and technology for the cryptoeconomy in the United States and internationally. It offers the primary financial account in the cryptoeconomy for consumers; a marketplace with a pool of liquidity for transacting in crypto assets for institutions; and technology and services that enable developers to build crypto-based applications and securely accept crypto assets as payment. The company was founded in 2012 and is based in Wilmington, Delaware.

NASDAQ ended the session with Coinbase dropping 11.53% to $57.10 on Monday while NASDAQ dropped 0.09% to $13,229.43.

Earnings Per Share

As for profitability, Coinbase has a trailing twelve months EPS of $-10.57.

More news about Coinbase.

6. Atento S.A. Ordinary Shares (ATTO) – -10.71%

Atento S.A., together with its subsidiaries, provides customer relationship management, and business process outsourcing services and solutions in Brazil, the Americas, Europe, the Middle East, and Africa. It offers a range of front and back-end services, including sales, customer care, technical support, collections, and back office, as well as applications-processing and credit-management. The company serves clients primarily in the telecommunications, banking, and financial services sectors; and in multi-sectors, including consumer goods, services, public administration, travel, healthcare, and transportation and logistics, as well as technology and media. It provides its services and solutions through digital channels, which include SMS, email, chats, social media and apps, and others, as well as through voice. The company was formerly known as Atento Floatco S.A. Atento S.A. was founded in 1999 and is based in Luxembourg.

NYSE ended the session with Atento S.A. Ordinary Shares sliding 10.71% to $2.50 on Monday, after two successive sessions in a row of gains. NYSE slid 0.35% to $15,291.17, after two consecutive sessions in a row of gains, on what was a somewhat negative trend trading session today.

Earnings Per Share

As for profitability, Atento S.A. Ordinary Shares has a trailing twelve months EPS of $-9.38.

More news about Atento S.A. Ordinary Shares.

7. Riot Blockchain (RIOT) – -8.67%

Riot Platforms, Inc., together with its subsidiaries, operates as a bitcoin mining company in North America. It operates through Bitcoin Mining, Data Center Hosting, and Engineering segments. The company also provides co-location services for institutional-scale bitcoin mining companies; and critical infrastructure and workforce for institutional-scale miners to deploy and operate their miners. In addition, it engages in the design and manufacturing of power distribution equipment and custom engineered electrical products; electricity distribution product design, manufacture, and installation services primarily focused on large-scale commercial and governmental customers, as well as a range of markets, including data center, power generation, utility, water, industrial, and alternative energy; operation of data centers; and maintenance/management of computing capacity. The company was formerly known as Riot Blockchain, Inc. Riot Platforms, Inc. was incorporated in 1998 and is based in Castle Rock, Colorado.

NASDAQ ended the session with Riot Blockchain dropping 8.67% to $10.69 on Monday, following the last session’s downward trend. NASDAQ slid 0.09% to $13,229.43, after two successive sessions in a row of gains, on what was a somewhat down trend exchanging session today.

Earnings Per Share

As for profitability, Riot Blockchain has a trailing twelve months EPS of $-4.19.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -48.54%.

Revenue Growth

Year-on-year quarterly revenue growth declined by 8.2%, now sitting on 252.62M for the twelve trailing months.

Sales Growth

Riot Blockchain’s sales growth is 20.2% for the current quarter and 70.1% for the next.

Moving Average

Riot Blockchain’s value is under its 50-day moving average of $10.71 and way higher than its 200-day moving average of $7.16.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Riot Blockchain’s EBITDA is 6.02.

More news about Riot Blockchain.

8. MicroStrategy (MSTR) – -8.5%

MicroStrategy Incorporated provides enterprise analytics software and services in the United States, Canada, Europe, the Middle East, Africa, and internationally. It offers MicroStrategy, an enterprise analytics software platform that enables users to create visualizations, customize apps, and embed analytics directly into workflows; and MicroStrategy Cloud Environment, a managed software-as-a-service solution, which offers always-on threat monitoring and enables rapid analytics development and deployment to deliver security and data privacy requirements. The company also provides MicroStrategy Support that helps customers to achieve their system availability and uptime goals, and to improve the overall experience through highly responsive troubleshooting and proactive technical product support. In addition, it offers MicroStrategy Consulting, which offers customers with architecture and implementation services to help them quickly realize results, as well as helps to achieve returns on investment derived from understanding of data; and MicroStrategy Education that provides free and paid learning options, as well as holds and acquires bitcoin. The company offers its services through enterprise sales force and channel partners. It serves companies from a range of industries, including banking, technology, consulting, manufacturing, insurance, healthcare, and telecommunications, as well as the public sector. The company was incorporated in 1989 and is headquartered in Tysons Corner, Virginia.

NASDAQ ended the session with MicroStrategy falling 8.5% to $276.45 on Monday, following the last session’s upward trend. NASDAQ dropped 0.09% to $13,229.43, after two consecutive sessions in a row of gains, on what was a somewhat negative trend trading session today.

Earnings Per Share

As for profitability, MicroStrategy has a trailing twelve months EPS of $-86.59.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -134.41%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, MicroStrategy’s stock is considered to be oversold (<=20).

Revenue Growth

Year-on-year quarterly revenue growth grew by 2.2%, now sitting on 501.9M for the twelve trailing months.

Moving Average

MicroStrategy’s worth is below its 50-day moving average of $297.16 and way higher than its 200-day moving average of $242.59.

More news about MicroStrategy.

9. Marathon (MARA) – -8.27%

Marathon Digital Holdings, Inc. operates as a digital asset technology company that mines digital assets with a focus on the blockchain ecosystem and the generation of digital assets in United States. The company was formerly known as Marathon Patent Group, Inc. and changed its name to Marathon Digital Holdings, Inc. in February 2021. Marathon Digital Holdings, Inc. was incorporated in 2010 and is headquartered in Fort Lauderdale, Florida.

NASDAQ ended the session with Marathon falling 8.27% to $9.20 on Monday, after four sequential sessions in a row of gains. NASDAQ dropped 0.09% to $13,229.43, after two consecutive sessions in a row of gains, on what was a somewhat bearish trend exchanging session today.

Earnings Per Share

As for profitability, Marathon has a trailing twelve months EPS of $-6.37.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -103.2%.

More news about Marathon.

10. Canaan (CAN) – -6.86%

Canaan Inc. engages in the research, design, and sale of integrated circuit (IC) final mining equipment products by integrating IC products for bitcoin mining and related components in the People's Republic of China. It is also involved in the assembly and distribution of mining equipment and spare parts. The company has operations in the United States, Australia, Kazakhstan, Hong Kong, Canada, Mainland China, Thailand, Sweden, and internationally. Canaan Inc. was founded in 2013 and is based in Singapore.

NASDAQ ended the session with Canaan falling 6.86% to $1.90 on Monday while NASDAQ dropped 0.09% to $13,229.43.

Earnings Per Share

As for profitability, Canaan has a trailing twelve months EPS of $-0.48.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.64%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Canaan’s stock is considered to be oversold (<=20).

Earnings Before Interest, Taxes, Depreciation, and Amortization

Canaan’s EBITDA is -0.11.

Moving Average

Canaan’s value is way below its 50-day moving average of $2.66 and way below its 200-day moving average of $2.89.

More news about Canaan.

Stay up to date with our winners and losers daily report